Cabaletta Bio, Inc.
CABA
NASDAQ·Healthcare·Biotechnology·Mkt cap $567.4M
$3.47
▼ -0.29%
P/E
-2.20
Mkt Cap
$567.4M
52-Wk Range
$1.56–$4.23
52-Week Range
$1.56 - $4.23
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 126.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CAAR T cell technology with novel mechanism of action targeting B cell-mediated autoimmune diseases
- Strategic partnerships with University of Pennsylvania and UC Regents providing research capabilities and credibility
- First-mover advantage in engineered T cell therapy for specific autoimmune indications with limited competitive landscape
- Multiple product candidates in pipeline reducing development risk and providing diversified revenue potential
Bear Case
1 risk
- Very high volatility (beta 3.3). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Advancement of DSG3-CAART through Phase I clinical trials toward potential Phase II initiation and accelerated regulatory pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-0.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CABA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$0.34 vs -$0.37 consensus (+8.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: Jefferies · Jun 3, 2026
vs Industry
How CABA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related